TLDR: Winship Cancer Institute of Emory University has partnered with Ryght AI, integrating into its Ryght Research Network to leverage advanced generative AI technology for revolutionizing clinical trial processes. This collaboration aims to enhance the precision and efficiency of site selection, streamline workflows, and accelerate access to life-saving therapies for cancer patients.
Winship Cancer Institute Joins Ryght AI Network to Advance AI-Powered Clinical Trials
Laguna Beach, CA / Atlanta, GA – July 11, 2025 – Ryght AI, a leader in real-time generative AI healthcare technology for clinical research, today announced a significant partnership with the prestigious Winship Cancer Institute of Emory University. Winship has officially joined Ryght’s unique Ryght Research Network, a global initiative designed to create an AI digital twin of every research site worldwide, thereby transforming the landscape of clinical trials.
This strategic collaboration marks a pivotal step in leveraging artificial intelligence to enhance the precision and efficiency of clinical trial operations. Distinguished academic institutions like Winship are now utilizing Ryght’s AI platform and applications to streamline workflows and revolutionize the entire clinical trial process.
Dr. Suresh Ramalingam, MD, FACP, FASCO, Executive Director of Winship Cancer Institute, expressed enthusiasm about the partnership, stating, “We are thrilled to join the Ryght Research Network bringing state-of-the-art AI solutions to our patients and staff. Our commitment to excellence in cancer research aligns perfectly with the goals of Ryght AI as we streamline our processes, accelerate access to potentially life-saving therapies.”
Winship Cancer Institute of Emory University, recognized as Georgia’s only National Cancer Institute (NCI)-designated comprehensive cancer center, is renowned for its academic research, patient-centric approach, and mission to positively transform cancer care. Its vision to improve outcomes for all cancer patients globally is directly aligned with Ryght AI’s objectives. By integrating into the Ryght Research Network, Winship will introduce innovative AI solutions to its constituents, poised to significantly enhance the depth and breadth of its clinical research and trial operations.
Ryght AI’s cutting-edge platform is designed to automate every step of clinical trial site selection, activation, and enrollment. The company’s innovative approach involves building a live “digital twin” profile for over 100,000 clinical research sites worldwide. This enables AI-recommended, data-driven site selection, automated feasibility assessments, and rapid activation on a SOC 2-compliant AI platform and network. Ryght AI aims to accelerate study startup, reduce costs, and improve patient access to new therapies by providing a real-time approach to synthetic outcome analysis, site identification, selection, and activation.
Simon Arkell, Co-Founder & CEO of Ryght AI, emphasized the shared vision, stating, “We are completely aligned with Winship Cancer Institute’s vision of improving the outcomes of all patients with cancer globally.”
Also Read:
- IQVIA Partners with NVIDIA to Launch Custom AI Agents for the Life Sciences Industry
- Accenture and Microsoft Deepen Partnership with Gen-AI Cybersecurity Initiative
The partnership underscores a shared commitment to accelerating medical breakthroughs and ensuring that life-saving therapies reach patients faster. By combining Winship’s clinical expertise and research prowess with Ryght AI’s advanced technological capabilities, this collaboration is set to make a profound impact on the future of cancer research and patient care.
